Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

This study has been completed.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Emory University
University of North Carolina, Chapel Hill
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Lori J. Wirth, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00392665
First received: October 24, 2006
Last updated: April 12, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2013
  Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)